Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 80 clinical trials
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with CIT.

advanced non-squamous non-small cell lung cancer
lung carcinoma
nivolumab
docetaxel
platinum-based chemotherapy
  • 229 views
  • 26 Aug, 2021
  • 199 locations
featured
  • 144 views
  • 25 Mar, 2021
  • 1 location
featured
Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

  • 140 views
  • 08 Nov, 2020
  • 1 location
featured
Advanced Colorectal or Lung Cancer Screening

Advanced Colorectal or Lung Cancer Screening

  • 158 views
  • 25 Mar, 2021
  • 1 location
SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

squamous non-small cell lung cancer
measurable disease
platinum-based chemotherapy
cancer
  • 0 views
  • 02 Aug, 2021
  • 18 locations
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in NSCLC

with unresectable, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC). Approximately 608 patients will be enrolled in this study from America, Europe, and Asia. Patients

  • 0 views
  • 25 Jan, 2021
  • 10 locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

(PFS) when compared to docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard

squamous non-small cell lung cancer
measurable disease
docetaxel
platinum-based chemotherapy
cancer
  • 23 views
  • 19 Sep, 2021
  • 218 locations
KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

pemetrexed
lung carcinoma
targeted therapy
carboplatin/paclitaxel
pembrolizumab
  • 2 views
  • 04 Sep, 2021
  • 28 locations
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na ve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B/KEYMAKER-U01B)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-nave participants with advanced squamous or non-squamous NSCLC

mk-3475
lung carcinoma
pembrolizumab
  • 0 views
  • 05 Sep, 2021
  • 27 locations
Staggered Chemo-Immunotherapy With Durvalumab MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.

pemetrexed
measurable disease
platelet count
durvalumab
cancer
  • 0 views
  • 28 Jun, 2021
  • 1 location